Med Ad News, PharmaLive.com sold

Share this article:

Med Ad News and PharmaLive.com publisher, Engel Publishing Partners, has been acquired by Los Angeles-based Canon Communications, Canon announced today. Financial terms of the deal were not disclosed.

Canon, a division of Apprise Media, produces magazine titles and trade shows focused on the medical device, specialty packaging, materials processing, and plastics processing industries.

Canon currently maintains several medical titles including MD&DI (Medical Device & Diagnostic Industry), Medical Product Manufacturing News, Medical Electronics Manufacturing, European Medical Device Manufacturer and others. Canon's digital media holdings include the medical device design and engineering portal, Medical Device Link; online magazine, Advanced Design & Manufacturing (AD&M) and various e-newsletters and e-publications.

Next month, Canon will launch its BIOMEDevice trade show, to provide “a forum for areas where the pharmaceutical and medical device manufacturing markets are converging,” said Charles McCurdy, Canon CEO.

Engel Publishing, based in Newtown, PA, was established in 1982. Its monthly Med Ad News publication covers business and marketing activities in the pharmaceutical industry.

Engel's R&D Directions title was established in 1995 and is published 10 times a year. R&D Directions' target audience is comprised of research and development professionals at pharmaceutical companies.

PharmaLive.com reports 150,000 unique visitors each month with 65,000 professionals registered to receive its e-newsletters.

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.